Skip to main content
Aurobindo Pharma Ltd. logo

Aurobindo Pharma Ltd. — Investor Relations & Filings

Ticker · AUROPHARMA ISIN · INE406A01037 LEI · 335800G4T2A353RDGM23 BSE.NS Manufacturing
Open in API
Filings indexed 1,427 across all filing types
Latest filing 2026-05-16 Legal Proceedings Report
Country IN India
Listing BSE.NS AUROPHARMA

About Aurobindo Pharma Ltd.

https://www.aurobindo.com/

Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.

Recent filings

Filing Released Lang Actions
General Updates
Legal Proceedings Report Classification · 87% confidence The document is an intimation under Regulation 30 of SEBI LODR notifying the stock exchanges and investors of a High Court order relating to SEBI settlement proceedings involving promoters. It provides details of a legal action and court order, which falls squarely under updates on significant lawsuits or regulatory actions (Legal Proceedings Report). Therefore, the appropriate classification is LTR.
2026-05-16 English
intimation of receipt of Order form the Hon''ble High Court of Telangana, Hyderabad by the promoters of the Company.
Regulatory Filings Classification · 80% confidence The document is an “intimation under Regulation 30” sent to stock exchanges detailing a court order and SEBI settlement, representing a compliance disclosure rather than a standalone financial report or a management change. It is not a full annual or interim report, nor an earnings release, nor is it a proxy or dividend notice. It is a routine regulatory announcement made under listing obligations. Therefore, it falls into the general Regulatory Filings category (RNS).
2026-05-16 English
Curateq Biologics Private Limited, a wholly owned subsidiary of the Company receives CDSCO Marketing Autorisation (Form CT 23) for Bevqolva (Bevacizumab Biosimilar).
Regulatory Filings Classification · 85% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, submitted to the National Stock Exchange and BSE. It informs the exchanges of a subsidiary’s receipt of a marketing authorization from the Central Drugs Standard Control Organization. There are no financial statements, earnings details, or other report content—this is a regulatory announcement filed with the stock exchanges. It best fits the fallback category “Regulatory Filings (RNS).”
2026-05-16 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an announcement under SEBI Regulation 30 to the stock exchanges notifying a regulatory approval (CDSCO marketing authorisation) for a subsidiary’s product. It contains no financial data, no voting results, no management changes, and is not a full report—it is a compliance/disclosure notice. This best fits the general Regulatory Filings category (RNS).
2026-05-16 English
Submission of certificate of extinguishment of 5423728 equity shares of Re.1/- of the Company bought back from the shareholders of the Company under Buyback Offer.
Transaction in Own Shares Classification · 90% confidence The document is an official stock exchange filing by Aurobindo Pharma Limited notifying the extinguishment of 54,23,728 equity shares bought back under SEBI Buyback Regulations, along with pre- and post-buyback share capital reconciliation and depository certificates. This is a report of the company’s own share repurchase and capital reduction. It is not a full financial report, dividend notice, voting result, or AGM material, but a transaction in own shares. Therefore, it fits the “Transaction in Own Shares” category.
2026-05-15 English
Closure of Buy Back
Transaction in Own Shares Classification · 95% confidence The document is a formal corporate announcement to stock exchanges regarding the extinguishment of 54,23,728 equity shares bought back by the company pursuant to SEBI Buy-Back Regulations, including reconciliation of share capital pre- and post-buyback. It is neither an earnings release nor a regulatory report attachment but a notification of the company’s own-share transaction (share repurchase extinguishment). This aligns with Transaction in Own Shares (Code: POS).
2026-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.